1e
19
1
49
2
2
18
1b
1d
18
36
47
1d
2 29
1d
25
Michael R. Rudnick, M.D.
88
47
Associate Professor CE of Medicine
28
80
3
5f
Chair, New and Existing Technology Committee, Penn Presbyterian Medical Center
17
39th and Market Stree
17
Philadelphia PA
11
Department: Medicine
4
1
b
1d
46
Contact information
49
4
3
3
3
2
29
49
Presbyterian Medical Center
1f 39th and Market Streets
1f Medical Office Building
2c Suite 240
Philadelphia, Pa 19104
26
1f 39th and Market Streets
1f Medical Office Building
2c Suite 240
Philadelphia, Pa 19104
30
Office: (215) 662-8730
34 Fax: (215) 243-4686
24
8f
34 Fax: (215) 243-4686
24
Email:
rudnickm@uphs.upenn.edu
12
rudnickm@uphs.upenn.edu
Links
bb Penn Presbyterian Medical Center
de Penn's Renal-Electrolyte and Hypertension Division
ad Penn Kidney Medicine Dialysis Care
122 Renal-Electrolyte and Hypertension Research Interests--Nephrology Clinical Research
c
4
b
1f
bb Penn Presbyterian Medical Center
de Penn's Renal-Electrolyte and Hypertension Division
ad Penn Kidney Medicine Dialysis Care
122 Renal-Electrolyte and Hypertension Research Interests--Nephrology Clinical Research
c
13
Education:
21 5 14 (Biology) c
2a Dickenson College, 1966.
21 9 B.A. 14 (Biology) c
28 LaSalle College, 1968.
21 9 M.D. c
32 Hahnemann Medical College, 1972.
c
3
3
3
3
8b
Permanent link21 5 14 (Biology) c
2a Dickenson College, 1966.
21 9 B.A. 14 (Biology) c
28 LaSalle College, 1968.
21 9 M.D. c
32 Hahnemann Medical College, 1972.
c
2 29
21
1e
1d
24
5e
27 Cardiac – Renal Interactions
65
39 Prevention of contrast media injury to the kidney
49 Renal Dysfunction in setting of cardiac disease and heart failure
1d Renovascular diseases
1c Kidney stone disease
4d Advanced Chronic Kidney Disease and management of the dialysis patient
1a 29
27
Description of Research Expertise
34 Contrast Media Injury to the Kidney27 Cardiac – Renal Interactions
65
Description of Clinical Expertise
26 Acute Kidney Injuries39 Prevention of contrast media injury to the kidney
49 Renal Dysfunction in setting of cardiac disease and heart failure
1d Renovascular diseases
1c Kidney stone disease
4d Advanced Chronic Kidney Disease and management of the dialysis patient
1a 29
23
15b Wang A., Holcslaw T., Bashore TM., Freed MI., Miller D., Rudnick MR., Szerlip H., Thames MD., Davidson CJ., Shusterman N., Schwab SJ.: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.[see comment] Kidney International 57(4): 1675-80, Apr 2000.
127 Berns JS., Rudnick MR., Cohen RM., Bower JD., Wood BC.: Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney International 56(1): 253-60, Jul 1999.
135 Ermer JC., Boni JP., Cevallos WH., DeCleene S., Burghart P., Rudnick MR., Fruncillo RJ., Berns JS., Cohen RM.: Bromfenac disposition in patients with impaired kidney function. Clinical Pharmacology & Therapeutics 61(3): 312-8, Mar 1997.
e5 Rudnick MR., Berns JS., Cohen RM., Goldfarb S.: Contrast media-associated nephrotoxicity. [Review] [150 refs] Seminars in Nephrology 17(1): 15-26, Jan 1997.
fa Rudnick MR., Berns JS., Cohen RM., Goldfarb S.: Contrast media-associated nephrotoxicity. [Review] [83 refs] Current Opinion in Nephrology & Hypertension 5(2): 127-33, Mar 1996.
13b Berns JS., Haghighat A., Staddon A., Cohen RM., Schmidt R., Fisher S., Rudnick MR., Tomaszewski JE.: Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients. Cancer 76(3): 497-500, Aug 1 1995.
16d Rudnick MR., Goldfarb S., Wexler L., Ludbrook PA., Murphy MJ., Halpern EF., Hill JA., Winniford M., Cohen MB., VanFossen DB.: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney International 47(1): 254-61, Jan 1995.
15d Revicki DA., Brown RE., Feeny DH., Henry D., Teehan BP., Rudnick MR., Benz RL.: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. American Journal of Kidney Diseases 25(4): 548-54, Apr 1995.
178 Roth D., Smith RD., Schulman G., Steinman TI., Hatch FE., Rudnick MR., Sloand JA., Freedman BI., Williams WW Jr., Shadur CA., et al.: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. American Journal of Kidney Diseases 24(5): 777-84, Nov 1994.
2c
7
1d
1f
Selected Publications
132 Rudnick MR., Goldfarb S.: Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. [Review] [31 refs] Reviews in Cardiovascular Medicine 4 Suppl 5: S28-33, 2003.15b Wang A., Holcslaw T., Bashore TM., Freed MI., Miller D., Rudnick MR., Szerlip H., Thames MD., Davidson CJ., Shusterman N., Schwab SJ.: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.[see comment] Kidney International 57(4): 1675-80, Apr 2000.
127 Berns JS., Rudnick MR., Cohen RM., Bower JD., Wood BC.: Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney International 56(1): 253-60, Jul 1999.
135 Ermer JC., Boni JP., Cevallos WH., DeCleene S., Burghart P., Rudnick MR., Fruncillo RJ., Berns JS., Cohen RM.: Bromfenac disposition in patients with impaired kidney function. Clinical Pharmacology & Therapeutics 61(3): 312-8, Mar 1997.
e5 Rudnick MR., Berns JS., Cohen RM., Goldfarb S.: Contrast media-associated nephrotoxicity. [Review] [150 refs] Seminars in Nephrology 17(1): 15-26, Jan 1997.
fa Rudnick MR., Berns JS., Cohen RM., Goldfarb S.: Contrast media-associated nephrotoxicity. [Review] [83 refs] Current Opinion in Nephrology & Hypertension 5(2): 127-33, Mar 1996.
13b Berns JS., Haghighat A., Staddon A., Cohen RM., Schmidt R., Fisher S., Rudnick MR., Tomaszewski JE.: Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients. Cancer 76(3): 497-500, Aug 1 1995.
16d Rudnick MR., Goldfarb S., Wexler L., Ludbrook PA., Murphy MJ., Halpern EF., Hill JA., Winniford M., Cohen MB., VanFossen DB.: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney International 47(1): 254-61, Jan 1995.
15d Revicki DA., Brown RE., Feeny DH., Henry D., Teehan BP., Rudnick MR., Benz RL.: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. American Journal of Kidney Diseases 25(4): 548-54, Apr 1995.
178 Roth D., Smith RD., Schulman G., Steinman TI., Hatch FE., Rudnick MR., Sloand JA., Freedman BI., Williams WW Jr., Shadur CA., et al.: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. American Journal of Kidney Diseases 24(5): 777-84, Nov 1994.
2c